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Macroautophagy is one of the major routes for 
the degradation of intracytoplasmic contents, in-
cluding proteins and organelles such as mitochon-
dria. The earliest morphologically recognizable 
intermediates in this pathway are phagophores, 
which evolve into double-membraned, sac-
shaped structures. After the edges of the phago-
phores extend and fuse, engulfing a portion of 
cytoplasm, they become known as autophago-
somes. These are then trafficked along micro-
tubules in a direction that is biased toward 
the perinuclear microtubule-organizing center, 
where the lysosomes are clustered. This brings 
the autophagosomes close to lysosomes, enabling 
fusion of these different organelles, after which 
the lysosomal hydrolases degrade the autopha-
gic contents (Fig. 1).
There are two additional forms of autoph-
agy that will not be considered in detail in this 
review. Microautophagy involves the direct se-
questration of portions of the cytoplasm by ly-
sosomes, and has been mainly studied in yeast. 
Chaperone-mediated autophagy captures pro-
teins that contain a pentapeptide motif related 
to KFERQ via Hsc70, which targets proteins to 
LAMP2A. LAMP2A then serves as a transloca-
tion channel to enable import of such substrates 
into the lysosomes. This pathway is perturbed 
by proteins causing certain neurodegenerative 
diseases and has been reviewed in detail else-
where (Cuervo and Wong, 2014).
Much of the pioneering work in the mac-
roautophagy (henceforth referred to as autoph-
agy in this review) field was initiated in yeast, 
where autophagy protects against cellular star-
vation. Although this role is conserved across 
evolution, more recent studies in mammalian 
systems have highlighted the importance of 
autophagy in diverse areas of physiology and 
disease. In this review, we will focus on the 
protective roles of autophagy in neurodegener-
ative and infectious diseases (Fig. 2). We will start 
by outlining the basic models where autophago-
somes engulf and degrade neurodegeneration-
associated aggregate-prone proteins or infectious 
agents. We will then describe possible mecha-
nisms for enhancing the capture of such sub-
strates to extents greater than would occur with 
bulk autophagy, during which one assumes there 
is random sequestration of cytoplasmic contents. 
We will extend the discussion of the roles of 
autophagy in these diseases by considering 
more complex consequences, including con-
trol of cell death, immunity, and inflammation. 
Although there are aspects that have been 
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Autophagy is a conserved process that uses double-membrane vesicles to deliver cytoplasmic 
contents to lysosomes for degradation. Although autophagy may impact many facets of 
human biology and disease, in this review we focus on the ability of autophagy to protect 
against certain neurodegenerative and infectious diseases. Autophagy enhances the clear-
ance of toxic, cytoplasmic, aggregate-prone proteins and infectious agents. The beneficial 
roles of autophagy can now be extended to supporting cell survival and regulating inflam-
mation. Autophagic control of inflammation is one area where autophagy may have similar 
benefits for both infectious and neurodegenerative diseases beyond direct removal of the 
pathogenic agents. Preclinical data supporting the potential therapeutic utility of autoph-
agy modulation in such conditions is accumulating.
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calcium flow from the ER to mitochondria, and the lower 
intramitochondrial calcium levels inhibit oxidative phosphory-
lation, thereby decreasing ATP levels, which activates AMPK 
(Cárdenas et al., 2010). Some signals activate autophagy by 
stimulating III phosphatidylinositol 3-kinase (called VPS34), 
which produces phosphatidylinositol 3-phosphate (PI3P); 
this, in turn, helps to recruit ATG16L1 to sites of autophago-
some formation (Dooley et al., 2014). Some of these signals 
act via the ATG6 orthologue Beclin 1, which stimulates 
VPS34 activity (Furuya et al., 2005; Russell et al., 2013). 
However, PI3P-independent forms of autophagy have also 
been described, and some of these appear to be mediated via 
the use of PI5P as an alternative to PI3P (Vicinanza et al., 
2015). Interestingly, many of the stimuli that induce autoph-
agy are stress responses. For example, mTORC1 activity is in-
hibited by amino acid starvation (Chen et al., 2014), the 
levels of PI5P are induced by glucose starvation (Vicinanza 
et al., 2015), and AMPK (a key sensor of ATP levels in 
the cells) is enhanced when ATP energy stores are reduced 
(Hardie et al., 2012). These pathways are also directly linked 
to antiinfective or general immune signaling players, such as 
IRGM (an antituberculosis and Crohn’s disease factor that 
interacts with ULK1 and Beclin 1, promoting their coassem-
bly; Chauhan et al., 2015), TAK1 and NOD2/RIPK2 (which 
activate AMPK and ULK1, respectively), and NLRP (which 
interacts with Beclin 1). The pathways also receive input 
from TLRs, IL-1, and other immune system regulators 
(Deretic et al., 2013).
In the context of neurodegenerative diseases such as 
Huntington’s disease (HD), there appears to be a decrease in 
mTORC1 activity in neurons with large aggregates (Ravikumar 
et al., 2004). However, the ultimate consequences for au-
tophagy may not be straightforward, as excitotoxicity will 
increase calcium levels, which in turn inhibits autophagosome 
biogenesis (Williams et al., 2008), whereas mutant huntingtin 
binds the autophagy inducer Rhes to impair autophagy (Mealer 
et al., 2014). Thus, the eventual consequences of a specific 
mutation or disease situation are frequently unpredictable, as 
multiple activating and inhibitory pathways may be affected. 
Furthermore, non–cell-autonomous effects may have an im-
pact. For example, the increased nitric oxide released by glial 
cells in diseases such as Alzheimer’s disease impairs autophago-
some biogenesis (Sarkar et al., 2011).
How autophagy clears aggregate-prone  
intracytoplasmic proteins
Intracellular protein misfolding and aggregation are features 
of many late-onset neurodegenerative diseases, which are re-
ferred to as proteinopathies. These include Alzheimer’s disease, 
Parkinson’s disease, tauopathies, and polyglutamine expan-
sion diseases (including HD and various spinocerebellar ataxias 
[SCAs]). Currently, there are no effective therapeutic strate-
gies that slow or prevent the neurodegeneration resulting from 
these diseases in humans. The mutations that cause HD and 
many other proteinopathies (e.g., polyglutamine diseases and 
tauopathies) confer novel toxic functions on the specific protein, 
explored more in neurodegenerative diseases than infectious 
diseases, and vice versa, we believe that the opportunity to 
consider both in parallel will enable consideration of new 
hypotheses and cross-fertilization. We propose that the two 
main areas of overlap between the roles of autophagy in neu-
rodegeneration and infectious disease are: (a) similarities in 
the shared usage of autophagic receptors in defending against 
pathology-inducing agents in both classes of disease (Birgisdottir 
et al., 2013), and (b) the now well-documented antiinflam-
matory action of autophagy (Deretic et al., 2013, 2015). This 
juxtaposition of autophagic roles in apparently distinct classes 
of diseases is a testament to the relevance of autophagy in 
cleansing the cellular interiors no matter what the disease con-
text is, and is particularly timely in view of the explosion of data 
in the two fields. Finally, we will consider possible autophagy-
related therapeutic strategies that may be of significance for 
these diseases, including the possibility of developing agents 
that may target both sets of conditions.
Autophagy biology
The membranes that contribute to phagophore formation 
and elongation may derive from multiple sources, including 
the ER (including ER exit sites and ER–mitochondrial con-
tact sites; Hayashi-Nishino et al., 2009; Hamasaki et al., 2013), 
the ER–Golgi intermediate compartment (Ge et al., 2013, 
2014), recycling endosomes (Longatti et al., 2012; Puri et al., 
2013), plasma membrane (Ravikumar et al., 2010; Moreau 
et al., 2011), the Golgi complex (Young et al., 2006; Ohashi 
and Munro, 2010), and, potentially, lipid droplets (Dupont 
et al., 2014; Shpilka et al., 2015). The coordination of the 
membrane rearrangements that enable autophagosome for-
mation, and their subsequent delivery to the lysosomes, is 
regulated by multiple autophagy-related (ATG) proteins. Some 
of these participate in two ubiquitin-like conjugation reac-
tions. The first involves ATG12 conjugation to ATG5. This 
ATG12–ATG5 conjugate binds noncovalently with ATG16L1 
to form a complex essential for phagophore expansion 
(Rubinsztein et al., 2012a). These complexes are localized to 
the phagophore and dissociate after the autophagosome is 
formed. The completion of autophagosome formation is as-
sisted by a second conjugation reaction involving ATG8/LC3. 
LC3 is first cleaved by ATG4 to form cytosolic LC3-I, which 
is conjugated to phosphatidylethanolamine on autophago-
some precursors to form membrane-associated LC3-II.
Autophagy signaling
A primordial signaling pathway regulating autophagy, which 
is conserved from yeast to humans, is mediated by the mam-
malian target of rapamycin complex 1 (mTORC1), which 
inhibits autophagy by phosphorylating proteins such as ATG1 
and ATG13 that act upstream in phagophore formation 
(Hosokawa et al., 2009; Jung et al., 2009). However, several 
mTORC1-independent pathways have been described, in-
cluding low inositol triphosphate levels (Sarkar et al., 2005), 
which activate autophagy by activating AMP-activated pro-
tein kinase (AMPK). Low inositol triphosphate levels reduce 
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inflammation (via recognition of damage-associated molec-
ular patterns [DAMPs]; Deretic et al., 2013). In addition, 
autophagy may also protect by enhancing the removal of rele-
vant toxins, such as Staphylococcus aureus -toxin (Maurer 
et al., 2015).
The direct elimination of microbes by autophagy (a pro-
cess termed xenophagy) receives the most attention, although 
it is likely that the antiinflammatory role of autophagy inde-
pendent of, or during, infection plays an equally important 
host protective role (Deretic et al., 2015). The former percep-
tion is understandable, as intracellular microbes such as invad-
ing bacteria or viruses are large intracytoplasmic objects that 
represent potential (and in many cases actual) substrates for 
autophagic removal. Prototypical examples of this are Myco-
bacterium tuberculosis in infected macrophages (Gutierrez et al., 
2004) and animal models (Castillo et al., 2012; Watson et al., 
2012; Manzanillo et al., 2013) and the Group A Streptococcus 
that manages to invade host cells (Nakagawa et al., 2004), but 
many other bacteria (including Listeria, Salmonella, and Shigella) 
are at least partially susceptible to autophagic elimination when 
tested in cellular systems (Gomes and Dikic, 2014; Huang and 
Brumell, 2014). Similarly, viruses, including HIV (Kyei et al., 
and disease severity frequently correlates with expression lev-
els. Thus, it is important to understand the factors regulating 
the expression levels of these aggregate-prone proteins. When 
these proteins are intracytoplasmic, they can be removed ei-
ther via the ubiquitin-proteasome system or via autophagy. 
Whereas the former route is generally more rapid, it is re-
stricted to species that can enter the narrow proteasome bar-
rel, which precludes oligomers and higher order structures. 
These species can be cleared by autophagy. Consistent with 
the model above, the aggregate-prone forms of such proteins, 
including tau (Berger et al., 2006), -synuclein (Webb et al., 
2003; Spencer et al., 2009), mutant huntingtin (Ravikumar 
et al., 2002), and mutant ataxin 3 (Berger et al., 2006) appear 
to have a higher dependency on autophagy for their clear-
ance compared with the wild-type forms.
Autophagy in infectious and inflammatory diseases
In the context of infectious and inflammatory diseases, autoph-
agy plays at least three roles. Autophagy can clear intracellular 
microbes and moderate host innate immune responses to mi-
crobial products (through recognition of pathogen-associated 
molecular patterns [PAMPs]) and endogenous sources of 
Figure . Schematic of autophagy. Activation of AMPK and/or inhibition of mTORC1 by various stress signals induces activation of the ATG1–ULK1 
complex, which positively regulates the activity of the VPS34 complex via phosphorylation-dependent mechanisms. Class III PI3K VPS34 provides PI3P to 
the phagophore, which seems to define the LC3-lipidation sites by assisting in the recruitment of the ATG12–ATG5–ATG16L1 complex to the membrane 
(asterisks). After the binding of ATG12–ATG5–ATG16L1 complex to the phagophore and LC3 conjugation to PE (LC3-II), the membrane elongates and en-
gulfs portions of the cytoplasm, ultimately leading to the formation of the complete autophagosome. Proteins such as p62, NDP52, and NBR1 confer 
substrate selectivity to the pathway by establishing a bridge between LC3-II and specific ubiquitinated cargo (e.g., aggregates, microbes, mitochondria, 
and peroxisomes), through their LIR and UBA domains, respectively. In the final step of the process, autophagosomes fuse with lysosomes, resulting in 
the degradation of the vesicle contents. AMPK, AMP-activated protein kinase; mTORC1, mechanistic target of rapamycin complex 1; ULK, Unc-51-like 
kinase; VPS34, phosphatidylinositol 3-kinase VPS34; PI3P, phosphatidylinositol 3-phosphate; PE, phosphatidylethanolamine; LIR, LC3-interacting region; 
UBA, ubiquitin associated domain.
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However, in several cases, evidence of microbial exploitation 
of autophagy (not just defense against it, but in some cases 
enhancing survival or promoting spread) suggests that this 
approach must be carefully tailored. Some examples of the 
latter include Brucella (Starr et al., 2008), Anaplasma (formerly 
Ehrlichia; Niu et al., 2012), and poliovirus (Bird et al., 2014).
Autophagy receptor proteins
Whereas autophagy was originally considered to be a nonse-
lective bulk degradation process, accumulating data now sup-
ports the concept of selective macroautophagy, where the cell 
uses receptor proteins to enhance the incorporation of spe-
cific cargoes into autophagosomes. These receptor proteins 
include p62 (Bjørkøy et al., 2005; Pankiv et al., 2007), opti-
neurin (Wild et al., 2011), NDP52 (Thurston et al., 2009), 
NBR1 (Kirkin et al., 2009), ALFY (Filimonenko et al., 2010), 
TRIM5 (Mandell et al., 2014), and Tollip (Lu et al., 2014). The 
canonical model for this process involves these receptors 
binding to cargoes, typically via interaction with ubiquitinated 
motifs, and the receptor binding to the autophagosome mem-
brane protein LC3 via LC3-interacting domains (Birgisdottir 
et al., 2013; Stolz et al., 2014). However, some classical recep-
tors, like p62 and NBR1, may not require LC3-binding to be 
2009; Shoji-Kawata et al., 2013; Mandell et al., 2014; Campbell 
et al., 2015; Sagnier et al., 2015), as well as protozoans (Choi 
et al., 2014), can be targeted by conventional or modified 
forms of autophagy. In many cases, an evolutionary balance 
exists whereby the host’s ability to deploy autophagy against 
the microbe is countered by bacterial or viral adaptations, and 
in most instances a successful intracellular pathogen has very 
specific antiautophagy strategies (Huang and Brumell, 2014). 
Such adaptations are seen in a wide range of pathogens, in-
cluding Shigella and Legionella (Huang and Brumell, 2014), 
Mycobacterium tuberculosis (Deretic et al., 2015), HSV-1 (Orvedahl 
et al., 2007; Lussignol et al., 2013), and HIV (Kyei et al., 
2009; Borel et al., 2014). Interestingly, interactions between 
autophagy and viral products can lead to neurological manifes-
tations; for example, HIV proteins have been associated with 
HIV-induced dementia and manifestations of neuroAIDS 
(Meulendyke et al., 2014; El-Hage et al., 2015; Fields et al., 
2015). As with other host–pathogen interactions, a balance 
between a microbe and the host is established, leading to 
chronic disease or subclinical or latent infection, as in latent 
tuberculosis or persistent viral infections. This represents a 
therapeutic opportunity to tip the balance against the pathogen 
by enhancing autophagy using pharmacological intervention. 
Figure 2. Protective roles of autophagy in neurodegenerative and infectious diseases. A major role for autophagy in neurodegenerative and in-
fectious diseases involves the clearance of toxic aggregate-prone proteins and infectious agents, respectively. However, it also exerts ancillary beneficial 
roles by controlling cell death and exacerbated inflammatory responses associated with these pathologies.
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(Ravikumar et al., 2006; Hou et al., 2010; Amir et al., 2013; 
Meunier et al., 2014). In a manner similar to what has been 
observed in yeast, autophagy inhibition sensitizes mammalian 
cells to nutrient deprivation, whereas autophagy compromise 
results in apoptosis (Boya et al., 2005). Consistent with this, 
autophagy activation protects against proapoptotic insults in 
culture and in vivo. This may be relevant in neurodegenera-
tive diseases, where subapoptotic caspase activities may en-
hance disease by processes including cleavage of proteins like 
mutant huntingtin (Wellington et al., 2002; Warby et al., 
2008) or tau (Rohn et al., 2002) to increase their toxicities, 
or by trimming of dendritic spines (Pozueta et al., 2013; Ertürk 
et al., 2014).
Autophagy also regulates inflammation. As recently re-
viewed (Deretic et al., 2015), the antiinflammatory functions 
of autophagy in principle involve: (a) prevention of spurious 
inflammasome activation and down-regulation of the response 
once inflammasome is activated (Saitoh et al., 2008; Nakahira 
et al., 2011; Zhou et al., 2011; Lupfer et al., 2013) and (b) in-
hibition of type I IFN responses directly (Jounai et al., 2007; 
Saitoh et al., 2009; Konno et al., 2013; Liang et al., 2014) or 
indirectly (Tal et al., 2009; Liang et al., 2014). The underly-
ing processes include autophagic elimination of endogenous 
DAMPs (e.g., depolarized mitochondria leaking ROS, mito-
chondrial DNA, and oxidized mitochondrial DNA; Saitoh 
et al., 2008; Nakahira et al., 2011; Zhou et al., 2011; Lupfer 
et al., 2013), which lowers the threshold for inflammasome 
activation, or direct targeting and degradation of inflamma-
some components and products such as NLRP3, ASC, and 
IL-1 (Harris et al., 2011; Shi et al., 2012; Chuang et al., 2013); 
this, in turn, tapers the intensity and duration of inflammasome 
activation. However, the engagement of autophagy with cel-
lular outputs of IL-1, a prototypical unconventionally secreted 
protein, is more complex (Dupont et al., 2011; Ponpuak et al., 
2015). Autophagy assists secretion of IL-1 (Dupont et al., 
2011; Öhman et al., 2014; Wang et al., 2014), a cytosolic 
protein that lacks a signal peptide and is unable to enter the 
conventional secretory pathway via the ER and Golgi. Thus, 
autophagy also plays a positive role in delivering IL-1 and 
possibly other proinflammatory substrates, once they are prop-
erly activated in the cytosol, to the extracellular space where 
they perform their signaling functions (Ponpuak et al., 2015).
The autophagic interference with type I IFN responses 
occurs either directly by targeting signaling molecules within 
the pathway, starting with RIG-I-like receptors or cGAMP 
synthase (sensors recognizing cytosolic nucleic acids) and con-
verging upon stimulator of the interferon gene (STING) and 
interferon regulatory factors (Jounai et al., 2007; Saitoh et al., 
2009; Konno et al., 2013; Liang et al., 2014), or indirectly by 
removing agonist sources that activate these pathways (Tal 
et al., 2009; Liang et al., 2014). The p62 receptor also appears 
to have a role in restraining TCR activation of NF-B sig-
naling mediated by Bcl10. Although p62 enables the signal-
ing to occur in the first place, it also serves as a receptor to 
degrade Bcl10, which becomes ubiquitinated as a response to 
TCR activation. Thus, this mechanism may serve to protect 
incorporated into autophagosomes (Itakura and Mizushima, 
2011). Although systematic studies have not yet been per-
formed, many of these receptors, including p62 and optineurin, 
appear to be able to assist autophagic capture of both neuro-
degenerative disease-causing proteins and infectious agents. 
In their antimicrobial role, these receptors are referred to as 
a new class of pattern recognition receptors termed sequesto-
some 1/p62-like receptors (Birgisdottir et al., 2013; Deretic 
et al., 2013, 2015). The ability of receptor proteins to recruit 
substrates to autophagosomes can also be modulated by post-
translational modifications. For example, the TANK-binding 
kinase 1 (TBK1) phosphorylates optineurin on Ser177, enhanc-
ing LC3-binding affinity and autophagic clearance of substrates, 
such as expanded polyglutamines as seen with mutant hun-
tingtin (Korac et al., 2013), and Salmonella (Wild et al., 2011). 
Likewise, TBK1- (Pilli et al., 2012) or casein kinase-mediated 
(Matsumoto et al., 2011) phosphorylation of p62 at residue 
S403 has additional benefits in enhancing recognition of 
ubiquitinated targets by the ubiquitin-associated (UBA) do-
main of p62, as is observed in clearance of polyglutamine 
expansion targets (Matsumoto et al., 2011) or mycobacteria 
(Pilli et al., 2012). Enhancement of ubiquitin recognition by 
the p62 UBA is also under control of direct phosphorylation 
by ULK1, which phosphorylates Ser405 and Ser409 of mu-
rine p62 (equivalent to human Ser403 and Ser407; Lim et al., 
2015). ULK1-mediated phosphorylation of the former resi-
due additionally destabilizes the UBA dimer interface, thus 
increasing binding affinity of p62 to ubiquitin in response to 
proteotoxic stress (Lim et al., 2015). In the case of p62, and 
possibly other molecules, the activity of receptors can them-
selves be influenced by a disease protein. Huntingtin, the 
Huntington disease-causing protein, appears to act as a scaf-
fold for selective macroautophagy but it is dispensable for 
bulk autophagy (Ochaba et al., 2014; Rui et al., 2015). Hun-
tingtin interacts with p62 to enhance its interactions with 
LC3 and with ubiquitin-modified substrates (Rui et al., 2015). 
Interestingly, in some cases, such as with optineurin 
(Tumbarello et al., 2012) and TRIM5 (Mandell et al., 2014), 
the adaptor proteins themselves also can act as bulk autophagy 
regulators. It is interesting to note that several of these pro-
teins, including p62, TBK1, and optineurin, are mutated in 
neurodegenerative diseases such as motor neuron disease and 
forms of frontotemporal dementia (Maruyama et al., 2010; 
Fecto et al., 2011; Freischmidt et al., 2015; Pottier et al., 2015). 
Of further note is the shared role of autophagy receptors in 
protection against neurodegeneration and infectious agents, a 
principle that may extend to new receptor categories (e.g., 
TRIMs or other classes), as their functions are further eluci-
dated with future progress in selective autophagy.
Additional protective properties of autophagy  
in neurodegenerative and infectious diseases
A major consequence of autophagy in many of these diseases 
is promotion of the removal of toxic proteins or infectious 
agents, but there may be additional benefits. Autophagy is gen-
erally an antiapoptotic process that reduces caspase activation 
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trehalose (Frake et al., 2015; this work also considers the 
points of action of many of these drugs). Conversely, autoph-
agy inhibition enhances the toxicity of these proteins and, in 
parallel, leads to the accumulation of the relevant protein 
(Frake et al., 2015).
Similarly, autophagy up-regulation may enhance the clear-
ance of a range of infectious agents, with some of the more 
developed aspects being shown with M. tuberculosis, including 
multidrug-resistant (MDR) strains. In some cases, the support 
for this type of strategy has been strengthened by mouse models 
and preclinical data. For example, drugs used for psychiatric 
and neurological disorders such as the antidepressants fluox-
etine (Stanley et al., 2014) and nortriptyline (Sundaramurthy 
et al., 2013), and the antiepileptic carbamazepine (Rubinsztein 
et al., 2012b; Schiebler et al., 2015), have been shown to 
counter M. tuberculosis infection, possibly through autophagy. 
Notably, carbamazepine, an inducer of autophagy, has been 
shown to act on MDR M. tuberculosis in vivo (Schiebler et al., 
2015). Furthermore, several tyrosine kinase inhibitors, which 
also act as inducers of autophagy, have been tested in vitro 
and in mouse models for their potential in host-directed ther-
apy (HDT) in tuberculosis. This includes gefitinib, an inhibi-
tor of the tyrosine kinase epidermal growth factor receptor 
(EGFR) shown to activate autophagy and suppress M. tuber-
culosis in macrophages and, to some extent, in infected mice 
(Stanley et al., 2014). It also includes imatinib (Gleevec), a 
known inducer of autophagy (Ertmer et al., 2007) and in-
hibitor of the tyrosine kinase Abl, whose depletion has been 
shown to suppress intracellular M. tuberculosis (Jayaswal et al., 
2010), with imatinib reducing M. tuberculosis bacillary loads in 
infected macrophages (Bruns et al., 2012) and in a mouse 
model of tuberculosis (Napier et al., 2011). Other antituber-
culosis HDT autophagy-inducing candidate drugs include 
antiparasitic pharmaceuticals such as nitozoxanide (Lam et al., 
2012) and cholesterol-lowering drugs, i.e., statins (Parihar 
et al., 2014).
There may be a wide range of strategies that could be used 
in human conditions, including drugs (where several FDA-
approved drugs show promise in preclinical models), peptides 
(Shoji-Kawata et al., 2013), and possibly topical agents for 
certain infectious agents. Furthermore, there may be oppor-
tunities for modulating selective autophagy via adaptor pro-
teins. Strategies could include regulating posttranslational 
modifications of proteins that could enhance their activities.
Neurodegenerative disease-causing proteins and various 
infectious agents can also impair autophagy. Although this issue 
has been dealt with in detail elsewhere (Menzies et al., 2015), 
one recent example includes the VPS35 D620N Parkinson’s 
disease mutation that impacts early stages of autophagosome 
biogenesis (Zavodszky et al., 2014). PICALM, an Alzheimer’s 
disease GWAS hit, impacts both autophagosome formation 
and autophagosome degradation, and altered PICALM 
activity in culture and in vivo leads to the accumulation and 
increased toxicity of tau, a protein which is an important 
driver of Alzheimer’s disease pathogenesis (Moreau et al., 
2014). Likewise, infectious agents like Salmonella (Mesquita 
cells from NF-B hyperactivation in response to TCR sig-
naling (Paul et al., 2012). The antiinflammatory action of au-
tophagy applies to both infectious and inflammatory diseases 
(either sterile or associated with microbial triggers), such as 
Crohn’s disease. These relationships may extend to neuroin-
flammation in acute and chronic neurological disorders. 
Many neurodegenerative diseases are associated with inflam-
matory responses in glia, which may contribute to pathology 
(Czirr and Wyss-Coray, 2012), and it is possible that autophagy 
in glial cells may play a role in keeping these processes in check, 
although this domain has not been carefully explored.
Autophagy also plays key roles in protecting cells against 
infectious agents that either remain within vacuoles or escape 
from phagosomes into the cytoplasm (Huang and Brumell, 
2014). Examples of intracellular bacterial pathogens in most 
cases represent a mixed spectrum of retention within the para-
sitophorous vacuole, partial permeabilization of such vacu-
oles, or full escape of bacteria into the cytosol. Such mixed 
events are often skewed to one or the other end of the spec-
trum, with Shigella (Ogawa et al., 2005; Dupont et al., 2009; 
Mostowy et al., 2011; Ogawa et al., 2011; Thurston et al., 
2012) and Listeria (Py et al., 2007; Mostowy et al., 2011) pre-
dominantly escaping into the cytosol, whereas Salmonella 
(Zheng et al., 2009; Wild et al., 2011; Huett et al., 2012; 
Thurston et al., 2012; Gomes and Dikic, 2014) and M. tuber-
culosis (Gutierrez et al., 2004; Watson et al., 2012; Manzanillo 
et al., 2013; Deretic et al., 2015) primarily reside in undam-
aged vacuoles although recent studies indicate that it pene-
trates into the cytosol. Parallels may exist in neurodegenerative 
diseases, where autophagy may help glial cell clearance of 
extracellular -amyloid if the internalized peptide is found to 
gain access to the cytosol (Li et al., 2013). This principle may 
be also relevant to diseases like Parkinson’s disease and forms 
of frontotemporal dementia, where there is increasing evi-
dence for extracellular spread of the relevant toxic proteins 
like -synuclein and tau via prion-like mechanisms (Desplats 
et al., 2009; Frost et al., 2009; Lee et al., 2010; Steiner et al., 
2011). However, impaired clearance of autophagosomes due 
to defective lysosomal function may cause excess secretion of 
such proteins and exacerbate extracellular spread (Ejlerskov 
et al., 2013; Lee et al., 2013).
Therapeutic and clinical implications
Up-regulation of autophagy via mTORC1-dependent and 
-independent routes has been shown to enhance the clearance 
of neurodegenerative disease-causing proteins and reduce 
their toxicity in a wide range of cells in Drosophila, zebrafish, 
and mouse models (Ravikumar et al., 2004; Furuya et al., 2005; 
Sarkar et al., 2007; Zhang et al., 2007; Pickford et al., 2008; 
Menzies et al., 2010; Spilman et al., 2010; Cortes et al., 
2012; Schaeffer et al., 2012; Hebron et al., 2013; Frake et al., 
2015). This strategy has shown promise in a range of disease 
models, including tauopathies, -synucleinopathies, HD, spi-
nocerebellar ataxia type 3, and familial prion disease. The 
drugs used in these diseases include a rapamycin analogue and 
mTOR-independent autophagy inducers like rilmenidine and 
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may be partially mitigated if suitable iPS stem cell–derived neu-
ronal models are generated for sporadic cases. These difficul-
ties may be less of an issue for monogenic diseases that can be 
more faithfully recapitulated in mice. However, even in these 
cases, the disease course is often much more rapid in the mod-
els, which may have consequences for the way one interprets 
the preclinical data.
Future work will establish the potential for harnessing 
autophagy as a therapeutic option in various neurodegenera-
tive and infectious diseases.
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Note added in proof. While this manuscript was in production, further evidence 
of the extensive overlaps between inflammatory response systems and autophagy 
was documented in the context of cyclic GMP-AMP synthase (cGAS)-dependent type I 
IFN production and autophagic clearance of M. tuberculosis. (Collins, A.C., H. Cai, 
T. Li, L.H. Franco, X.D. Li, V.R. Nair, C.R. Scharn, C.E. Stamm, B. Levine, Z.J. Chen, and 
M.U. Shiloh. 2015. Cell host Microbe. 17:820-828; Watson, R.O., S.L. Bell, D.A. MacDuff, 
J.M. Kimmey, E.J. Diner, J. Olivas, R.E. Vance, C.L. Stallings, H.W. Virgin, and J.S. Cox. 
2015. Cell host Microbe. 17:811-819).
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